51 results about "Plasmodium sp" patented technology

This invention belongs to the field of organic synthetic chemistry technology, specifically relating to a selenium-based indoloquinazoline derivative, its preparation method, and its application, comprising: in an organic solvent, using aromatic amine compounds, malononitrile, and diselenoether as raw materials, in the presence of a palladium catalyst and an organic base, at 90°C... o The reaction was carried out under C conditions with stirring to obtain a selenyl indoline quinazoline derivative. This method features mild reaction conditions, simple operation, high yield, and good functional group compatibility, conforming to the principles of green chemistry. Furthermore, the selenyl indoline quinazoline derivative provided by this invention exhibits good inhibitory activity against Plasmodium, providing a drug lead compound for the development of novel antimalarial drugs and holding significant importance for the prevention and / or treatment of malaria.

An immunogenic composition comprising: a) one or more Plasmodium-derived ribosomal or ribosomal associated protein or immunogenic fragment thereof which has a sequence which is at least about 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to a ribosomal or ribosomal associated protein or an immunogenic fragment of a ribosomal or ribosomal associated protein recited in FIG. 1; or a ribosomal or ribosomal associated protein or peptide or immunogenic fragment thereof as recited in FIG. 2 or FIG. 3; and / or b) a polynucleotide encoding one or more protein, peptide or immunogenic fragment of a); wherein the immunogenic composition is for use in eliciting an immune response in a subject to treat or prevent malaria. Also provided are Plasmodium-derived ETRAMPs and / or histones, or immunogenic fragments thereof, for use in eliciting an immune response in a subject, preferably to treat or prevent malaria.

The present invention relates to ssDNA aptamers speciically binding to Plasmodium lactate dehydrogenase (LDH). The invention provides ssDNA aptamers having the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2, which are capable of binding LDH from at least Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. The aptamers enable in vitro detection of malaria independently of the infecting Plasmodium species and may be used in diagnostic compositions, kits, and biosensor-based detection systems.

The invention provides a composition comprising a Plasmodium species multimeric protein capable of forming a nanoparticle and at least one antigen of interest, wherein the multimeric protein comprises a monomer chosen from Plasmodium species pyridoxal 5'-phosphate synthase (PLP), chaperone 60 protein (Cpn60), and caseinolytic protease (Clp). In embodiments, the invention provides the composition wherein the monomers assemble to form a multimeric nanoparticle and / or which comprises an adjuvant. The invention further provides a nucleic acid encoding the multimeric protein and the at least one antigen of interest, E. coli comprising the nucleic acid, and the use of such in a method for producing the inventive multimeric protein and the at least one antigen of interest. Also provided are a method and use of the inventive multimeric protein and the at least one antigen of interest for immunizing a subject against Plasmodium species.

This invention provides a method for simultaneous detection of three bloodborne parasites based on RAA-LFS and its applications. First, target genes and primers for specifically amplifying the genomic DNA of Toxoplasma gondii, Babesia, and Plasmodium are screened, identifying primer and probe combinations specifically for amplifying the 18S rRNA-1 gene of Toxoplasma gondii, the 18S rRNA-2 gene of Babesia, and the 18S rRNA-3 gene of Plasmodium. Using RAA isothermal amplification technology, rapid multiplex detection is achieved in a single reaction system. Combined with lateral flow chromatography test strips for intuitive result interpretation, detection efficiency is greatly improved, and results are obtained in a short time. The RAA-LFS detection method provided by this invention has significant advantages in applications such as epidemic prevention and control or blood screening.

The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.

The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and / or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

Herein is described a method devised to cryopreserve mosquito eggs, viable upon subsequent thawing. The method reproducibly yields >25% hatched first instar larvae of Anopheles-species mosquitoes from cryopreserved eggs. The majority of hatched larvae continue to develop normally (87% pupation), through to adults (98%, 50% of which are female) which subsequently blood feed and produce viable second generation embryos that also develop normally. Adult mosquitoes obtained from cryopreserved embryos are able to be infected with Plasmodium falciparum gametocytes and produce salivary gland sporozoites in similar numbers to control mosquitoes.

The invention discloses a plasmodium vivax SNP (Single Nucleotide Polymorphism) molecular marker and application thereof in tracing. The SNP molecular marker provided by the invention can be used for effectively identifying plasmodium vivax in the inland of China. According to the invention, one SNP molecular marker is identified and obtained through a PCR method, and then plasmodium vivax is traced. According to the invention, plasmodium vivax DNA traceability is carried out by adopting a PCR method based on the SNP molecular marker, the method has the characteristics of convenience and rapidness, the SNP molecular marker stably and widely exists in plasmodium vivax genome DNA, and large-scale popularization of the traceability technology is facilitated.

The invention relates to application of a TNF-alpha antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention. In order to solve the problems that in the prior art, the drug resistance of chemical drugs is prominent, efficient vaccines are lacked, and mosquito-stage transmission blocking means are insufficient, TNF-alpha antibodies are injected into plasmodium infected hosts to block binding of host TNF-alpha and mosquito wengen receptors, so that IMD channels are activated, expression of anti-malarial effector factors TEP1 is promoted, and development of plasmodium in mosquito bodies is inhibited; meanwhile, the occurrence rate of host cerebral malaria is reduced, and the transmission blocking effect can be synergistically enhanced by combining with the anti-Pfs25 antibody. The method is accurate in targeting, specifically intervenes a TNF-alpha signal channel, and avoids non-specific damage; dual protection: synchronously blocking mosquito propagation and preventing severe malaria of a host; the blocking efficiency is remarkably improved by combining with the anti-Pfs25 antibody, and a new strategy is provided for malaria prevention and control.

The invention provides a plasmodium infection stage detection method and system, and the method comprises the steps: obtaining a plasmodium image, carrying out the marking of the plasmodium image, determining a corresponding infection stage, constructing a preliminary data set through the marked plasmodium image, and carrying out the data processing of the preliminary data set, and determining a plasmodium infection stage image data set; constructing a ResNet-based plasmodium infection stage detection framework, and designing a convolution block attention module in a feature fusion module of the ResNet framework; constructing a mixed loss function to optimize the detection architecture; and training the constructed detection architecture according to the plasmodium infection stage image data set to determine a target plasmodium infection stage detection architecture. The method solves the problem that in the prior art, a plasmodium infection stage detection method for accurately and rapidly identifying irregular forms of plasmodium in different infection stages is lacked.

The invention belongs to the technical field of plasmodium falciparum pigment detection, and particularly relates to a plasmodium falciparum pigment content detection method and application thereof. The plasmodium falciparum pigment content detection method comprises the following steps: resuspending erythrocytes infected by plasmodium falciparum by using a solvent, adding saponin, uniformly mixing, standing, centrifuging, and collecting precipitate to obtain plasmodium falciparum coarse precipitate. And centrifuging the plasmodium falciparum coarse precipitate, and collecting the precipitate to obtain the plasmodium falciparum precipitate. And re-suspending the plasmodium falciparum precipitate by using an SDS solution, repeatedly centrifuging and collecting the precipitate until the absorbance value at 400nm in the centrifuged supernatant is zero, collecting the precipitate, adding the SDS solution and a NaOH solution for dissolving, detecting the absorbance value at the wavelength of 400nm, and calculating to obtain the content of the plasmodium falciparum pigment. The plasmodium falciparum pigment content detection method does not need complex technologies such as Raman spectrum and magnetic separation, and the pigment level and forming ability of plasmodium can be rapidly screened and determined.

The invention belongs to the technical field of molecular biological detection, and relates to a polypeptide for detecting asymptomatic infection of plasmodium vivax malaria and application. The polypeptide for detecting the asymptomatic infection of the malaria of the plasmodium vivax is an amino acid sequence as shown in SEQ ID No.1, or a homologous sequence which is subjected to substitution, deletion or insertion of one or more amino acids or has the sequence similarity greater than 75%. The polypeptide has an amino acid sequence as shown in SEQ ID No. 1. The polypeptide SEQ ID No.1 in the invention specifically detects asymptomatic tertian malaria infection, and can effectively deal with tertian malaria input threats in the Burmese border area. Meanwhile, the polypeptide can be coated in a detection tool of a rapid detection kit, and the tool has the characteristics of portability, high efficiency, low cost and the like, and is suitable for field sample detection in a malaria prevalence area.

The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

The present disclosure relates to synthetic Plasmodium reticulocyte binding protein 2b (mRBP2b) antigens that have improved properties such as thermal stability, as well as the use of these antigens to detect a Plasmodium infection in a diagnostic device or for use in a vaccine.

The invention belongs to the field of molecular biology and biomedical engineering, and particularly relates to a primer group for plasmodium genus and species identification and a colorimetric detection method based on loop-mediated isothermal amplification (LAMP). The primer group comprises a primer group of plasmodium and a specific primer group between plasmodium species; wherein the primer group (Pan-Plasmodium (Pan)) of the plasmodium is sequence information (5 '-3'), and the specific details are recorded in the specification. And through the optimally designed LAMP reaction system and the chromogenic reaction of the magnesium ion by-product and the pH indicator, the identification result of the sample can be judged, the detection efficiency is improved, and the visual instant detection of the plasmodium species is realized. Compared with existing microscope detection and rapid diagnosis test paper, the test paper has the advantages of short detection time, high sensitivity, strong specificity and the like, and provides a new technical means for accurate diagnosis, prevention and control of malaria.

The present invention relates to a compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. The invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating plasmodium related diseases such as malaria.

The utility model discloses a kind of plasmodium infection rapid detection devices, including detection table, finger setting groove and containment groove are set in the left side of detection table, first electric telescopic rod is fixedly installed in containment groove, blood taking needle is detachably installed in the upper end of first electric telescopic rod, slidingly connected with door type frame on the surface of strip board, the side of door type frame is provided with lysing solution adding mechanism, second electric telescopic rod is fixedly connected with the lower surface of door type frame, the lower surface of second electric telescopic rod is fixedly connected with suspension, blood extraction mechanism and pressing ring are fixedly connected with the surface of suspension. Stretching and contracting by first electric telescopic rod, blood taking needle can be pierced through through-hole to break patient's finger, by setting second electric telescopic rod elongation, can drive suspension, blood extraction mechanism and pressing ring to move down, by blood extraction mechanism to discharge patient blood to detection card, it can be used to complete plasmodium rapid test work using detection card, effectively improve detection efficiency.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of Plasmodium circumsporozoite protein (CSP) antigens and related techniques (e.g., components thereof and / or methods related thereto). The present disclosure provides, among other things, a polyribonucleotide comprising a coding sequence encoding a full-length Plasmodium CSP polypeptide. In some embodiments, the full-length Plasmodium CSP polypeptide comprises a Plasmodium CSP N-terminal domain, and the coding sequence of the polyribonucleotide encoding the full-length Plasmodium CSP polypeptide has a particular nucleotide content as provided herein.

The invention discloses a pyrimidine-hydroxamic acid compound as well as a preparation method and application thereof. The compound has a general formula as shown in a formula I. The compound can be used as a small-molecule inhibitor of histone deacetylase (HDAC), has strong anti-malaria activity, has a remarkable killing effect on various wild and drug-resistant plasmodium, and has the potential of being developed into an anti-malaria drug with a novel action mechanism.

The disclosure belongs to the technical field of biomedicine, and specifically relates to an application of DHA@ZIF-8 in the treatment of experimental cerebral malaria. In the disclosure, an experimental cerebral malaria model is first established. Subsequently, DHA@ZIF-8 is used for treatment in the model, and the therapeutic efficacy of the nanodrug against experimental cerebral malaria is evaluated using behavioral, pathological, and molecular biological techniques. In the disclosure, the use of ZIF-8 as a carrier achieves the effect of slowly releasing the drug, prolonging the duration of action of the drug in vivo, so as to more effectively kill Plasmodium. Compared with natural administration, this approach extends the duration of action of DHA.

The invention relates to a process for producing an antimalarial vaccine composition containing the recombinant chimeric protein SEQ ID NO: 2, which comprises a conserved region I, targeted by neutralising antibodies, linked to an immunodominant region containing repeats of central amino acids from the different alleles (VK210, P. vivax-like and VK247) of the circumsporozoite protein (PvCSP), predominant on the surface of sporozoites, the infective form of Plasmodium vivax, followed by the C-terminal domain region, target of T lymphocytes, of the PvCSP protein. It also relates to the vaccine composition produced by said process, which is directed at malaria caused by Plasmodium vivax and presents high immunogenicity and protection, with efficacy superior to that of the compositions presented in the prior art. The process revealed in this technology allows the production of a high-purity API (100% by RP-HPLC and 98.8% by SE-HPLC) with a high yield (5,082.5 mg from 3L of purified supernatant).

The present disclosure relates to a composition for inhibiting cross-species infection of malaria caused by Plasmodium vivax in a subject. Preferably, the disclosed compositions are prepared in the form of a vaccine comprising: a plurality of polynucleotides, each of the plurality of polynucleotides comprising a sequence as set forth in SEQ ID No.1 or SEQ ID No.2, expressed in the subject for inducing an immune response responsive to a malaria infection thereof; a liquid phase of lipid nanoparticles, the liquid phase of lipid nanoparticles configured to form a protective layer, the protective layer encapsulating a plurality of polynucleotides within the protective layer; and a pharmaceutically acceptable adjuvant.

The invention discloses a plasmodium image intelligent identification method based on deep learning, and belongs to the technical field of medical data processing. The method comprises the following steps: firstly, carrying out standardized preparation and image acquisition pretreatment on a plasmodium blood smear, and preliminarily screening a live plasmodium sample through electrode treatment and induction; data sets are divided through expert labeling, a multi-scale feature fusion classification model is constructed, sample imbalance is relieved by adopting weighted cross entropy loss, and the performance of the model is improved in combination with nested balance online distillation; and finally, through model test evaluation, outputting a visual identification report containing plasmodium types, development periods and positions. The method solves the problem of insufficient identification accuracy caused by small sample and sample imbalance in the prior art, gives consideration to the identification precision and efficiency, can assist the clinical rapid and accurate diagnosis of malaria, and meets the application requirements of primary medical institutions.

The invention relates to the technical field of non-coding RNA (Ribonucleic Acid) of parasites, and discloses a method for researching regulation and control of variant antigen genes of plasmodium non-coding RNA, which comprises the following steps: S1, constructing a modified plasmid pLN-ENR-GFP by overexpression plasmid: replacing a promoter region with a plasmodium falciparum U6 promoter; after PCR amplification, carrying out HindIII / EcoRI double enzyme digestion on a product, and inserting the product into a pLN-ENR-GFP carrier; adding a 9 * T terminator at the 3'end, introducing EcoRI / ApaI enzyme cutting sites at the two ends, and carrying out enzyme cutting connection: inserting an RUF6-15 fragment into the modified pLN-ENR-GFP vector; s2, synchronization of plasmodium and plasmid transfection and synchronization: taking a plasmodium falciparum in-vitro culture with a plasmodium falciparum body proportion of more than 60% in a cyclic body stage, and adding 5% of D-sorbitol (1 ml of cell volume: 14 ml of sorbitol); according to the method for researching the regulation and control of the variant antigen gene of the plasmodium non-coding RNA, a plasmodium falciparum RUF6-15 transgenic overexpression strain (138nt) is constructed, efficient and stable expression of target ncRNA is realized through optimization of a U6 promoter (SEQ ID NO: 1) and a PolyT terminator, and the technical bottleneck of functional verification of medium-length ncRNA of the plasmodium is broken through.

Systems, compositions, devices, methods, etc., provide improved anti-malaria immunological responses comprising making, providing and administering vaccines comprising specific RNA molecules such as self-replicating replicon RNA (repRNA) encoding proteins from Plasmodium such as the P. yoelii (Py) CS protein (CSP), including in some embodiments substantially target proteins encoding target antigens, for example a whole or substantially whole CSP in the repRNA. The prime-and-trap intervals for the administration of the vaccine can comprise administration of only a single dose of a repRNA-Non-encapsulating oil-in-water emulsion nanocarriers (e.g., LION™) component followed by administration of as few as 3 or 2 doses, or even just a single dose, of the WO component (e.g., RAS or genetically attenuated WO) at 0 day (same day), or 1, 2, 3, 4, 5, 10, 14, 15 days or 28 days later.

The application belongs to the technical field of genetic engineering, and particularly relates to a Plasmodium berghei gene modified strain and application thereof in screening of a transmission blocking agent. The application discloses, for the first time, a nucleotide sequence of a sexual stage gene PBANKA_1112700 of Plasmodium berghei and an amino acid sequence of a protein coded by the gene. By constructing an HA-tagged strain, it is determined that the gene is highly expressed in a ookinete stage and located on a membrane surface. By constructing a gene knockout strain, it is proved that the gene is inhibited after being knocked out, and ookinete formation and mosquito stomach oocyst formation are inhibited. The application provides application of PBANKA_1112700 as a malaria transmission blocking candidate gene, and provides a theoretical and experimental basis for research and development of a novel malaria transmission blocking.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related techniques (e.g., components thereof and / or methods related thereto) for delivering plasmodium protein antigens. In addition, the present disclosure provides a combination comprising a first pharmaceutical composition comprising a first polyribonucleotide and a second pharmaceutical composition comprising a second polyribonucleotide. In some embodiments, the first polyribonucleotide encodes a first polypeptide comprising one or more plasmodium T cell antigens. In some embodiments, the second polyribonucleotide encodes a second polypeptide comprising one or more Plasmodium polypeptides (e.g., CSPs), or antigenic portions thereof.